136 related articles for article (PubMed ID: 12602079)
21. Bayesian estimation of cost-effectiveness: an importance-sampling approach.
Heitjan DF; Li H
Health Econ; 2004 Feb; 13(2):191-8. PubMed ID: 14737756
[TBL] [Abstract][Full Text] [Related]
22. A new approach for sample size calculation in cost-effectiveness studies based on value of information.
Bader C; Cossin S; Maillard A; Bénard A
BMC Med Res Methodol; 2018 Oct; 18(1):113. PubMed ID: 30348087
[TBL] [Abstract][Full Text] [Related]
23. Using covariates to reduce uncertainty in the economic evaluation of clinical trial data.
Vázquez-Polo FJ; Negrín Hernández MA; López-Valcárcel BG
Health Econ; 2005 Jun; 14(6):545-57. PubMed ID: 15497202
[TBL] [Abstract][Full Text] [Related]
24. Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio.
O'Hagan A; Stevens JW; Montmartin J
Pharmacoeconomics; 2000 Apr; 17(4):339-49. PubMed ID: 10947489
[TBL] [Abstract][Full Text] [Related]
25. Economic endpoints in clinical trials.
Cook J; Drummond M; Heyse JF
Stat Methods Med Res; 2004 Apr; 13(2):157-76. PubMed ID: 15068259
[TBL] [Abstract][Full Text] [Related]
26. A Bayesian model averaging approach with non-informative priors for cost-effectiveness analyses.
Conigliani C
Stat Med; 2010 Jul; 29(16):1696-709. PubMed ID: 20572119
[TBL] [Abstract][Full Text] [Related]
27. Using full probability models to compute probabilities of actual interest to decision makers.
Harrell FE; Shih YC
Int J Technol Assess Health Care; 2001; 17(1):17-26. PubMed ID: 11329842
[TBL] [Abstract][Full Text] [Related]
28. Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section.
Cooper NJ; Sutton AJ; Abrams KR
Stat Methods Med Res; 2002 Dec; 11(6):491-512. PubMed ID: 12516986
[TBL] [Abstract][Full Text] [Related]
29. An illustration of the modelling of cost and efficacy data from a clinical trial.
Hahn S; Whitehead A
Stat Med; 2003 Mar; 22(6):1009-24. PubMed ID: 12627415
[TBL] [Abstract][Full Text] [Related]
30. Handling uncertainty in economic evaluations of patient level data: a review of the use of Bayesian methods to inform health technology assessments.
McCarron CE; Pullenayegum EM; Marshall DA; Goeree R; Tarride JE
Int J Technol Assess Health Care; 2009 Oct; 25(4):546-54. PubMed ID: 19845985
[TBL] [Abstract][Full Text] [Related]
31. Bayesian analysis: a new statistical paradigm for new technology.
Grunkemeier GL; Payne N
Ann Thorac Surg; 2002 Dec; 74(6):1901-8. PubMed ID: 12643371
[TBL] [Abstract][Full Text] [Related]
32. The iterative use of economic evaluation as part of the process of health technology assessment.
Sculpher M; Drummond M; Buxton M
J Health Serv Res Policy; 1997 Jan; 2(1):26-30. PubMed ID: 10180650
[TBL] [Abstract][Full Text] [Related]
33. Bayesian clinical trials in action.
Lee JJ; Chu CT
Stat Med; 2012 Nov; 31(25):2955-72. PubMed ID: 22711340
[TBL] [Abstract][Full Text] [Related]
34. A decision-theoretic approach to Bayesian clinical trial design and evaluation of robustness to prior-data conflict.
Calderazzo S; Wiesenfarth M; Kopp-Schneider A
Biostatistics; 2022 Jan; 23(1):328-344. PubMed ID: 32735010
[TBL] [Abstract][Full Text] [Related]
35. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
36. Clinical trials in critical care: can a Bayesian approach enhance clinical and scientific decision making?
Yarnell CJ; Abrams D; Baldwin MR; Brodie D; Fan E; Ferguson ND; Hua M; Madahar P; McAuley DF; Munshi L; Perkins GD; Rubenfeld G; Slutsky AS; Wunsch H; Fowler RA; Tomlinson G; Beitler JR; Goligher EC
Lancet Respir Med; 2021 Feb; 9(2):207-216. PubMed ID: 33227237
[TBL] [Abstract][Full Text] [Related]
37. Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease.
Claxton K; Neumann PJ; Araki S; Weinstein MC
Int J Technol Assess Health Care; 2001; 17(1):38-55. PubMed ID: 11329844
[TBL] [Abstract][Full Text] [Related]
38. Selection of the treatment effect for sample size determination in a superiority clinical trial using a hybrid classical and Bayesian procedure.
Ciarleglio MM; Arendt CD; Makuch RW; Peduzzi PN
Contemp Clin Trials; 2015 Mar; 41():160-71. PubMed ID: 25583273
[TBL] [Abstract][Full Text] [Related]
39. Bayesian designs and the control of frequentist characteristics: a practical solution.
Ventz S; Trippa L
Biometrics; 2015 Mar; 71(1):218-226. PubMed ID: 25196832
[TBL] [Abstract][Full Text] [Related]
40. Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study.
Miners AH; Garau M; Fidan D; Fischer AJ
BMJ; 2005 Jan; 330(7482):65. PubMed ID: 15601681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
